CORINNOVA INCORPORATED

Basic Information

7000 FANNIN ST STE 1950-D
HOUSTON, TX, 77030-5400

http://www.corinnnov.com

Company Profile

CorInnova is developing breakthrough medical technologies to treat heart disease and promote heart recovery based on an understanding of the vital role of mechanical factors in heart development, disease, and treatment. CorInnova's first product is an innovative non-blood contacting biventricular cardiac assist device which not only has significant advantages over existing circulatory assist devices, but which may also lead to a breakthrough in treating heart failure by promoting restorative remodeling of the heart. CorInnova's technology addresses a critical unmet worldwide medical need - the shortage of transplants and the lack of safe, effective treatments for the end stage heart failure population.

Additional Details

Field Value
DUNS: 154150341
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: 4


  1. Development of a Hybrid Dynamic Stent

    Amount: $148,233.00

    DESCRIPTION (provided by applicant): Though drug-eluting stents have successfully reduced restenosis rates in coronary applications, they have not proven as effective in peripheral applications. There ...

    SBIR Phase I 2012 Department of Health and Human Services
  2. SBIR Phase I: Pre-clinical Development of Device to Guide Heart Recovery via Assist and Support

    Amount: $100,000.00

    This Small Business Innovation Research (SBIR) Phase I project is focused on a novel therapy for heart failure that employs device mediated intervention to guide cardiac growth, remodeling, and recove ...

    SBIR Phase I 2009 National Science Foundation
  3. Proactive Modulation of Strain for Ventricular Recovery

    Amount: $725,068.00

    DESCRIPTION (provided by applicant): Congestive heart failure (CHF) is a debilitating condition that afflicts nearly 5 million Americans, and it has an increasing incidence. Despite improvements and ...

    STTR Phase II 2006 Department of Health and Human Services
  4. Proactive Modulation of Strain for Ventricular Recovery

    Amount: $99,998.00

    DESCRIPTION (provided by applicant): Congestive heart failure (CHF) is a debilitating condition that afflicts nearly 5 million Americans, and it has an increasing incidence. Despite improvements and ...

    STTR Phase I 2005 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government